Gastroenteropancreatic Neuroendocrine Tumors: Update on Therapeutics
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Gastroenteropancreatic Neuroendocrine Tumors: Update on Therapeutics
Authors
Keywords
-
Journal
ANNALS OF PHARMACOTHERAPY
Volume 46, Issue 6, Pages 851-862
Publisher
SAGE Publications
Online
2012-05-16
DOI
10.1345/aph.1q729
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Somatostatin analogs for the treatment of neuroendocrine tumors
- (2011) Michael D. Culler et al. CANCER AND METASTASIS REVIEWS
- Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors
- (2011) Eric Raymond et al. CANCER AND METASTASIS REVIEWS
- Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers
- (2011) Anna Imhof et al. JOURNAL OF CLINICAL ONCOLOGY
- Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting
- (2011) Matthew H. Kulke et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas
- (2010) Jonathan R. Strosberg et al. CANCER
- Pancreatic Endocrine Tumors
- (2010) Kjell Öberg SEMINARS IN ONCOLOGY
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
- (2009) Anja Rinke et al. JOURNAL OF CLINICAL ONCOLOGY
- Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
- (2009) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms
- (2008) S. Grozinsky-Glasberg et al. ENDOCRINE-RELATED CANCER
- Targeting Vascular Endothelial Growth Factor in Advanced Carcinoid Tumor: A Random Assignment Phase II Study of Depot Octreotide With Bevacizumab and Pegylated Interferon Alfa-2b
- (2008) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study
- (2008) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors
- (2008) Anne O'Donnell et al. JOURNAL OF CLINICAL ONCOLOGY
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States
- (2008) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors
- (2008) Matthew H. Kulke et al. JOURNAL OF CLINICAL ONCOLOGY
- ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biotherapy
- (2008) Kjell Öberg et al. NEUROENDOCRINOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation